Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management
- PMID: 20030429
- DOI: 10.2165/11318600-000000000-00000
Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management
Abstract
Elderly individuals are susceptible to autoimmune bullous dermatoses (ABDs), which may be associated with high morbidity and mortality. ABDs result from an autoimmune response to components of the basement membrane zone at the dermal-epidermal junction or desmosomes. Bullous pemphigoid results from autoimmunity to hemidesmosomal proteins present in the basement membrane of stratified squamous epithelia. Patients present with tense blisters in flexural areas of the skin. Mild disease may be treated with potent topical corticosteroids, while extensive disease usually requires systemic corticosteroids or systemic immunosuppressive agents such as azathioprine. Mucosal pemphigoid affects one or more mucous membranes that are lined by stratified squamous epithelia. The two most commonly involved sites are the eye and the oral cavity. Lesions frequently result in scar formation that may cause blindness. Patients with severe disease or ocular involvement require aggressive therapy with corticosteroids and cyclophosphamide. Epidermolysis bullosa acquisita results from autoimmunity to type VII collagen in the anchoring fibrils of the basement membrane. Lesions may either arise on an inflammatory base or be non-inflammatory and result primarily from trauma. Treatment options include corticosteroids, dapsone, ciclosporin, methotrexate and plasmapheresis/immunoapheresis. Paraneoplastic pemphigus results from autoimmunity to multiple desmosomal antigens. The disorder is associated with neoplasms, especially leukaemia, lymphoma and thymoma. Patients present with stomatitis and polymorphous skin eruption. The disease may respond to successful treatment of the underlying neoplasm or may require immunosuppressive therapy.
Similar articles
-
Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.An Bras Dermatol. 2019 Apr;94(2 Suppl 1):33-47. doi: 10.1590/abd1806-4841.2019940207. Epub 2019 Jun 30. An Bras Dermatol. 2019. PMID: 31166405 Free PMC article.
-
Autoimmune bullous dermatoses in the elderly: diagnosis and management.Drugs Aging. 2003;20(9):663-81. doi: 10.2165/00002512-200320090-00004. Drugs Aging. 2003. PMID: 12831291 Review.
-
Autoimmune bullous diseases: diagnosis and management.Dermatol Nurs. 2006 Feb;18(1):20-5. Dermatol Nurs. 2006. PMID: 16550892 Review.
-
Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease.J Pathol. 2012 Sep;228(1):1-7. doi: 10.1002/path.4062. Epub 2012 Jul 26. J Pathol. 2012. PMID: 22692770
-
Retrospective analysis of autoimmune bullous diseases in Middle Franconia.Front Immunol. 2023 Oct 10;14:1256617. doi: 10.3389/fimmu.2023.1256617. eCollection 2023. Front Immunol. 2023. PMID: 37881435 Free PMC article.
Cited by
-
Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.An Bras Dermatol. 2019 Apr;94(2 Suppl 1):33-47. doi: 10.1590/abd1806-4841.2019940207. Epub 2019 Jun 30. An Bras Dermatol. 2019. PMID: 31166405 Free PMC article.
-
Thymoma and autoimmunity.Cell Mol Immunol. 2011 May;8(3):199-202. doi: 10.1038/cmi.2010.74. Epub 2011 Feb 14. Cell Mol Immunol. 2011. PMID: 21317916 Free PMC article. Review.
-
Epidermolysis bullosa acquisita.An Bras Dermatol. 2022 Jul-Aug;97(4):409-423. doi: 10.1016/j.abd.2021.09.010. Epub 2022 Jun 11. An Bras Dermatol. 2022. PMID: 35701269 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical